Psoriasis Clinical Trial

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Summary

The objective of the study is to evaluate the safety and efficacy of a topical lotion.

View Full Description

Full Description

The objective of the study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult subjects with moderate to severe plaque psoriasis.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Male or female, of any race, at least 18 years of age (inclusive).
Freely provides both verbal and written informed consent.
Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this calculation.
Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.
Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or 4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this assessment).

Key Exclusion Criteria:

Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the investigator.
Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the investigator.
Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the investigator.
Is pregnant, nursing an infant, or planning a pregnancy during the study period.
Has received treatment with any investigational drug or device within 60 days or 5 drug half lives (whichever is longer) prior to the Baseline visit, or is concurrently participating in another clinical study with an investigational drug or device.

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

203

Study ID:

NCT02462070

Recruitment Status:

Completed

Sponsor:

Bausch Health Americas, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 16 Locations for this study

See Locations Near You

Valeant Site 3
Mobile Alabama, 36601, United States
Valeant Site 9
Beverly Hills California, 90210, United States
Valeant Site 12
Encino California, 91316, United States
Valeant Site 10
San Diego California, 92093, United States
Valeant Site 1
Santa Rosa California, 95403, United States
Valeant Site 16
Denver Colorado, 80123, United States
Valeant Site 2
Tampa Florida, 33601, United States
Valeant Site 7
South Bend Indiana, 46601, United States
Valeant Site 8
Louisville Kentucky, 40202, United States
Valeant Site 13
Clinton Township Michigan, 48036, United States
Valeant Site 14
Rochester New York, 14603, United States
Valeant Site 6
Nashville Tennessee, 37115, United States
Valeant Site 5
Austin Texas, 73344, United States
Valeant Site 4
Houston Texas, 77001, United States
Valeant Site 11
Norfolk Virginia, 23501, United States
Valeant Site 15
Spokane Washington, 99201, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

203

Study ID:

NCT02462070

Recruitment Status:

Completed

Sponsor:


Bausch Health Americas, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider